Cardiovascular Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bristol-Myers Squibb Company
Pharmaceutical firm reports earnings per share of $0.38
December 7th, 2004
Bristol-Myers Squibb Company (BMY) reported net earnings of $758 million on sales of $5.4 billion for the third quarter of 2004. Fully diluted earnings per share for the quarter were $0.38, or $0.44 on a non-GAAP basis, excluding specified items. "This was a solid quarter for our growth drivers across our businesses and geographies, including our newer products - Abilify, Reyataz and Erbitux," said Peter R. Dolan, chairman and chief executive officer. "We are hopeful about significant further growth potential for these products, with additional indications for Abilify and Reyataz achieved this past quarter. In addition, our...
Source: Cardiovascular Business Week (2004-12-07)
|
